Navigation Links
Genta Updates Progress of its Phase 3 Trial of Genasense(R) in Patients with Advanced Melanoma
Date:6/24/2008

guide-lines for diagnosis and treatment of skin cancer, and it provides direction, coordination and organizations of clinical, therapeutic, and experimental trials.

About Genasense

Genasense inhibits production of Bcl-2, a protein made by cancer cells that is thought to block chemotherapy-induced apoptosis (programmed cell death). By reducing the amount of Bcl-2 in cancer cells, Genasense may enhance the effectiveness of current anticancer treatment. Genta is pursuing a broad clinical development program with Genasense evaluating its potential to treat various forms of cancer.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drug as paclitaxel and docetaxel. Ganite and Genasense are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.
'/>"/>

SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. FDA Lifts Clinical Hold on Gentas Tesetaxel, a Leading Oral Taxane
2. Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology
3. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Prevention of Diabetic Foot Infections
4. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers
5. Genta Receives Key Patent Related to Oral Gallium Compound G4544
6. Genta Incorporated Announces Fourth Quarter and Year End 2007 Financial Results and Corporate Highlights
7. Innocoll Announces Dosing of First Patient in Second US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections
8. Innocoll Announces Dosing of First Patient in US Phase 3 Clinical Trial to Investigate CollaRx(R) GENTAMICIN SURGICAL IMPLANT for the Prevention of Surgical Site Infections in Cardiac Surgery Patients
9. Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Mildly Infected Diabetic Foot Ulcers
10. Genta Clinical Programs Featured at American Society of Hematology Meeting
11. Genta Completes Initial Clinical Dosing of G4544, a New Oral Drug for Bone Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... AUSTIN, Texas , Sept. 4, 2015  Luminex ... will present at the Morgan Stanley Global Healthcare Conference ... the Grand Hyatt Hotel in New York ... begin at 11:40 a.m. Eastern time on Friday, September ... be accessed at Luminex Corporation,s website at http://www.luminexcorp.com ...
(Date:9/4/2015)... PUNE, India , September 4, 2015 ... "Apheresis Market by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, Leukapheresis, and ... by Technology and by Product - Global Forecast to ... expected to reach USD 2.5 Billion by 2020, growing ... from 2015 to 2020. Browse 139 ...
(Date:9/4/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... upcoming Rodman & Renshaw 17 th Annual Global ... New York City .  Dr. Michael ... overview on September 9, 2015. Presentation ...
Breaking Medicine Technology:Luminex Corporation To Present At The Morgan Stanley Global Healthcare Conference 2Apheresis Market Worth 2.5 Billion USD by 2020 2Apheresis Market Worth 2.5 Billion USD by 2020 3Apheresis Market Worth 2.5 Billion USD by 2020 4Apheresis Market Worth 2.5 Billion USD by 2020 5Oramed to Present at the Rodman & Renshaw Global Investment Conference 2Oramed to Present at the Rodman & Renshaw Global Investment Conference 3
... Pharmaceuticals, Inc., a private, specialty pharmaceutical company focused on ... nervous system (CNS) diseases and trauma, announced today that ... treatment of acute migraine attacks, from the specialist healthcare ... the precise cause of migraines is not fully understood, ...
... Cohera Medical, a rapidly growing medical device company, announced today ... 50 Awards. Cohera Medical was recognized as the 2011 Life ... Executive Officer, Patrick Daly, was named Pittsburgh CEO of the ... by the Pittsburgh Technology Council as a company that is ...
Cached Medicine Technology:Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine 2Ariel Pharmaceuticals, Inc. Acquires Novel Compound for Acute Migraine 3Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards 2Cohera Medical and CEO Receive Pittsburgh Tech 50 Awards 3
(Date:9/4/2015)... ... September 04, 2015 , ... Scalability Experts (SE) announced that ... at this year’s Microsoft Worldwide Partner Conference that was held in Orlando, Florida. ... Winner for Data Platform services, the 2015 HP and Microsoft “Outstanding Frontline Partner” ...
(Date:9/4/2015)... Francisco, CA (PRWEB) , ... September 04, 2015 ... ... Amini, announces that CEREC technology is now available at CitiDent. CEREC is a ... machinery. In addition to saving time for patients by eliminating the need for ...
(Date:9/4/2015)... ... 2015 , ... Mike Day, a former Navy SEAL who was shot 27 ... Championships in Kona on October 10th. , Mike is running the race to raise ... and the cutting-edge treatments that restore their quality of life. More than ...
(Date:9/4/2015)... ... September 04, 2015 , ... ... of personal humidifying medical devices, announced its only mission and research focus: Water ... Research Founder Sharon Kleyne, body water evaporation is becoming dangerously accelerated. As a ...
(Date:9/4/2015)... ... September 04, 2015 , ... The conference program for ... Florida October 9-10, 2015 at the Diplomat Resort & Spa has been announced ... and researchers at the top of their field and will be presenting sessions ...
Breaking Medicine News(10 mins):Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 2Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 3Health News:Scalability Experts is Awarded Three Separate 2015 “Partner of the Year” Awards at Microsoft’s Worldwide Partner Conference 4Health News:San Francisco Dentist, Dr. Ben Amini, is Now Offering CEREC Technology at CitiDent 2Health News:Navy SEAL Shot 27 Times Competes in Ironman World Championship in Kona to Raise Money for Veteran's Suffering from TBI and PTSD 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... Awards go to Henry Ford Health System, MSU, ... 2008 Five Michigan researchers whose,work has helped ... research dollars totaling $50,000 through Blue Cross Blue ... Awards., The researchers are from Henry Ford ...
... 2008 Protection against,vaccine-preventable diseases is not only ... clinicians aware of the importance of,complete and timely ... Practice has published a supplement to the April ... your community adequately,protected?, Based on a recently ...
... Characterization of Dry-Patch ... Vaccine -, ... announced it will receive a,cost-reimbursement grant for up to $943,856 from the ... a,patch-based version of the anthrax vaccine., Under the 1-year grant, Iomai ...
... Just Plain Fraudulent Asks Top Acupuncture Physician, ... when you,thought it was safe to get acupuncture ... the right to be shamelessly under qualified. This,time ... ordinary to "cure" asthma,ADD, hot flashes, post-stroke injury, ...
... Two Hospitals in the System - Sentara Heart Hospital ... Beach General Hospital ... - Novadaq(R) Technologies Inc.,(TSX: NDQ), a developer of real-time ... today announced that Sentara Heart,Hospital(R) in Norfolk, Virginia and ...
... TAMPA, Fla., April 8, 2008 A Tampa-area ... medical reporting,systems that allows physicians to gain approval ... with patients as a result., As medical ... -- making patients wait longer for procedures and,giving ...
Cached Medicine News:Health News:Researchers Able to Continue their Work to Help Patients Thanks to McDevitt Excellence in Research Awards from Blue Cross Blue Shield of Michigan Foundation 2Health News:Adults Need Protection Against Vaccine-Preventable Diseases, Too 2Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 2Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 3Health News:Iomai Wins Department of Defense Grant to Develop a Stable, Patch-Based Anthrax Vaccine 4Health News:SNAP! CRACKLE! POP! Untrained Chiropractors Doing Acupuncture! 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 2Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 3Health News:Virginia's largest Cardiac Surgery program adopts SPY as standard of care 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: